Evidence map›Paper›PMID 30872721›Full record

ArticleScientific reports2019

Tracking Decitabine Incorporation into Malignant Myeloid Cell DNA in vitro and in vivo by LC-MS/MS with Enzymatic Digestion.

Sujatha Chilakala, Ye Feng, Lan Li, Reda Mahfouz, Ebrahem Quteba, Yogen Saunthararajah, Yan Xu

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06923488 (Phase I/II Study of Leflunomide in Combination With Decitabine for Treatment of Relapsed or Refractory), which is not on this map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06923488 phase1 / phase2recruitingnot on this mapstarted 2025, after this paper: background citation

Phase I/II Study of Leflunomide in Combination With Decitabine for Treatment of Relapsed or Refractory (R/R) Myelodysplastic Syndromes (MDS)

TypeinterventionalSponsorWest Virginia UniversityRan2025 to 2028Enrolled26ConditionsMyelodysplastic SyndromesArmsLeflunomide 10mg, Leflunomide 20mg, Decitabine
3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Review
  3. [CLAG±DAC regimen in the treatment of refractory/relapsed acute myeloid leukemia].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2024
    Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Sujatha ChilakalaDepartment of Chemistry, Cleveland State University, 2121 Euclid Avenue, Cleveland, Ohio, 44115, USA.
Ye FengDepartment of Chemistry, Cleveland State University, 2121 Euclid Avenue, Cleveland, Ohio, 44115, USA.
Lan LiDepartment of Chemistry, Cleveland State University, 2121 Euclid Avenue, Cleveland, Ohio, 44115, USA.
Reda MahfouzDepartment of Hematology and Oncology, Taussig Cancer Institute, Cleveland Clinic, 2010 East 90th Street, Cleveland, OH, 44195, USA.ORCID 0000-0003-4250-9422
Ebrahem QutebaDepartment of Hematology and Oncology, Taussig Cancer Institute, Cleveland Clinic, 2010 East 90th Street, Cleveland, OH, 44195, USA.
Yogen SaunthararajahDepartment of Hematology and Oncology, Taussig Cancer Institute, Cleveland Clinic, 2010 East 90th Street, Cleveland, OH, 44195, USA.
Yan XuDepartment of Chemistry, Cleveland State University, 2121 Euclid Avenue, Cleveland, Ohio, 44115, USA. y.xu@csuohio.edu.
Cleveland State University · USCleveland Clinic · US

Funding

TUMOR METABOLISM PROGRAMP30CA043703 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI MARK R CHANCE · 1987 to 2026
$142.3M
Optimizing decitabine regimen + formulation for nonDNA damaging DNMT1 depletionR01CA138858 · NCI · CLEVELAND CLINIC LERNER COM-CWRU · PI SAUNTHARARAJAH, YOGEN · 2009 to 2013
$1.6M
NCI NIH HHS P30 CA043703NCI NIH HHS R01 CA138858
6 · The paper itself

Abstract

The DNA hypomethylating agents decitabine and 5-azacytidine are the only two drugs approved for treatment of all subtypes of the myeloid malignancy myelodysplastic syndromes (MDS). The key to drug activity is incorporation into target cell DNA, however, a practical method to measure this incorporation is un-available. Here, we report a sensitive and specific LC-MS/MS method to simultaneously measure decitabine incorporation and DNA hypomethylation. A stable heavy isotope of 2'-deoxycytidine was used as an internal standard and one-step multi-enzyme digestion was used to release the DNA bound drug. Enzyme-released decitabine along with other mononucleosides were separated by a reverse-phase C

Indexed as

AnimalsAntimetabolites, AntineoplasticApoptosisCell ProliferationChromatography, LiquidDecitabineDNA MethylationDNA, NeoplasmEndonucleasesExonucleasesHumansIn Vitro TechniquesLeukemia, Myeloid, AcuteMiceMyelodysplastic SyndromesTandem Mass SpectrometryAntimetabolites, AntineoplasticDecitabineDNA, NeoplasmEndonucleasesExonucleases

Identifiers

PMID30872721
PMCPMC6418203
OpenAlexW2921042490

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.